RNAi modulation of HIF-1 and therapeutic uses thereof

Details RNAi modulation of HIF-1 and therapeutic uses thereof RNAi modulation of HIF-1 and therapeutic uses thereof

2006-06-27

2010-06-15

Zara, Jane (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S006120, C435S091100, C435S455000, C536S023100, C536S024310

Reexamination Certificate

active

07737265

ABSTRACT:
The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1α, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.

REFERENCES:
patent: 5000000 (1991-03-01), Ingram et al.
patent: 5595760 (1997-01-01), Cherif-Cheikh
patent: 5672659 (1997-09-01), Shalaby et al.
patent: 5902880 (1999-05-01), Thompson
patent: 6107094 (2000-08-01), Crooke
patent: 6146886 (2000-11-01), Thompson
patent: 6395713 (2002-05-01), Beigelman et al.
patent: 7217572 (2007-05-01), Ward et al.
patent: 2004/0180357 (2004-09-01), Reich et al.
patent: 2005/0026164 (2005-02-01), Zhou
patent: 2005/0107325 (2005-05-01), Manoharan et al.
patent: WO 94/02595 (1994-02-01), None
patent: WO 96/10390 (1996-04-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/10392 (1996-04-01), None
patent: WO 00/53722 (2000-09-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 2006/038208 (2004-07-01), None
patent: WO 2004/064737 (2004-08-01), None
patent: WO 2004/080406 (2004-09-01), None
patent: WO 2004/094345 (2004-11-01), None
patent: WO 2004/094595 (2004-11-01), None
patent: WO2007/002718 (2007-01-01), None
Peracchi, A. et al., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Chirila, T. et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Crooke, S. Antisense Research & Application, Chapter 1, pp. 1-50 Springer-Verlag, Publ. (S. Crooke, Ed.) (1998).
Branch, A. Trends in Biochem. Sci., vol. 23, pp. 45-50 (1998).
Opalinska, J.B. et al., Nature Reviews, vol. 1, pp. 503-514 (2002).
Akhtar et al., “Cellular Uptake and Intracellular Fate of Antisense Olligonucleotides”,Trends in Cell Biology, 2:139-144, (1992).
Aldrian-Herrada et al., “A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to aretro-inversodelivery peptide. The antisense activity depresses the targed mRNA and protein in magnocellular oxytocin neurons”,Nucleic Acid Research, 26(21): 4910-4916, (1998).
U.S. Appl. No. 60/559,917, filed May 4, 2004, Zimmermann et al.
Banai et al., “Upregulation of Vascular Endothelial Growth Factor Expression Induced by Myocardial Ischaemia: Implications for Coronary Angiogenesis”,Cardiovascular Research, 28: 1176-1179, (1994).
Boado et al., “Anitsense Drug Delivery Throught the Blood-Brain Barrier”,Advanced Drug Delivery Reviews, 15: 73-107, (1995).
Boado et al., “Drug Delivery of Anitsense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebrail AIDS”,Journal of Pharmaceutical Sciences, 87(11): 1308-1315, (1998).
Couture et al., “Anti-Gene Therapy: The Use of Ribozymes to Inhibit Gene Function”,Trends in Genetics, 12(12): 510-515 (1996).
Elbashir et al., “RNA Interference in Mediated by 21- and 22-Nucleotide RNAs”,Genes&Development, 15: 188-200 (2001).
Fire et al., “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans”, Nature, 391: 806-811 (1998).
Firth et al., “Oxygen-regulated control elements in the Phosphoglycerate Kinase 1 and Lactate dehydrogenase A genes: Similarities with the erythropoietin 3′ enhancer”,Proc. Natl. Acad. Sci. USA, 91: 6496-6500, (1994).
Goldberg et al., “Regulation of Erythropoietin Gene: Evidence That the Oxygen Sensor is a Heme Protein”,Science, 242: 1412-1415 (1988).
Goldberg et al., “Similarities between the Oxygen-sensing Mechanisms Regulating the Expression of Vascular Endothelial Growth Factor and Erythropoietin”,The Journal of Biological Chemistry, 269(6): 4355-4359, (1994).
Gonzalez et al., “New Class of Polymers for the Delivery of Macromolecular Therapeutics”,Bioconjugate Chem.10: 1068-1074, (1999).
Hofland et al., “Formulation and Delivery of Nucleic Acids”,Novel Therapeutics from Modern Biotechnology, 8: 166-172 Springer (Berlin), (1999).
Ishiwata et al., “Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholosteryl Ether”,Chemical and Pharmaceutical Bulletin, 43(6): 1005-1011(1995).
Jelkman, W., “Erythropoietin: Structure, Control of Production, and Function”,Physcological Reviews, 72 (2): 449-489, (1992).
Jolliet-Riant et al., “Drug Transfer Across the Blood-Brain Barrier and improvement of Brain Deliver”,Fundamental Clin. Pharmacol.13: 16-26, (1999).
Lasic et al., “The Stealth Liposome: A Prototypical Biomaterial”,American Chemical Society, 95(8): 2601-2628 (1995).
Lasic et al., “Liposomes Revisted”,Science, 267(5205): 1275-1276 (1995).
Lee et al., “Modified Liposome Formulations for Cytosolic Delivery of Macromolecules”,ACS Symposium Series, 752: 184-192 (2000).
Limbach et al., “Summary: The Modified Nucleosides of RNA”,Nucleic Acids Research, 22(12): 2183-2196, (1994).
Liu et al., Cationic Liposome-mediated Intravenous Gene Delivery,The Journal of Biological Chemistry, 270(42): 24864-24870 (1995).
Maurer et al., “Lipid-based Systems for the Intracellular Delivery of Genetic Drugs”,Molecular Membrane Biology, 16: 129-140, (1999).
Maxwell et al., “Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: Evidence for a widespread oxygen-sensing mechanism”,Proc. Natl. Acad. Sci. USA, 90: 2423-2427 (1993).
Nykanen et al., “ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway”,Cell, 107: 309-321, (2001).
Oku et al., “Real-time Analysis of Liposomal Trafficking in Tumor Bearing Mice by Use of Positron Emission Tomography”,Biochimica et Biophysica Acta1238: 86-90 (1995).
Pardridge et al., “Vector-Medicated Delivery of a Polyamide (“Peptide”) Nucleic Acid Analogue through the Blood-Brain Barrier in vivo”,Proc. Natl. Acad. Sci.USA 92: 5592-5596 (1995).
Semenza et al., “Regulation of Erythropoietin Production”,Hematology/Oncology Clinics of North America, 8(5): 863-884 (1994).
Semenza et al., “Transcriptional Regulation of Gene Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor 1*”, The Journal of Biological Chemistry, 269(38): 23757-23763 (1994).
Schweiki et al., “Vascular Endothelial Growth Factor Induced by Hypoxia May Mediate Hypoxia-Initiated Angiogenesis”,Nature, 359: 843-845, (1992).
Tyler et al., “Peptide Nucleic Acids Targeted to the Neurotensin Receptor and Administered I.P. cross the blood-brain barrier and specifically reduce gene expression”,Proc. Natl. Acad. Sci. USA, 96: 7053-7058 (1999).
Tyler et al., “Specific Gene Blockade Shows that Peptide Nucleic Acids Readily Enter Neuronal Cells in vivo”,FEBS Letters421: 280-284 (1998).
Wang et al., “General Involvement of Hypoxia-Inducible Factor 1 in Transcriptional Response to Hypoxia”,Proc. Natl. Acad. Sci. USA90: 4304-4308 (1993).
White et al., “Coronary Collateral Development in Swine After Coronary Artery Occlusion”,Circulation Research, 71: 1490-1500, (1992).
Wolfe et al., “Short-Term Modulation of Glycogen Metabolism, Glycosis and Gluconeogenesis by Physiological Oxygen Concentrations in Hepatocyte Cultures”,Eur. J. Biochem., 135: 405-412 (1983).

Affiliated with

Also associated with

Rating

RNAi modulation of HIF-1 and therapeutic uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with RNAi modulation of HIF-1 and therapeutic uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi modulation of HIF-1 and therapeutic uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4239056